Last reviewed · How we verify
Omnicef (CEFDINIR)
Omnicef (cefdinir) is a cephalosporin antibacterial drug, a type of small molecule antibiotic. It was originally developed and is currently owned by Abbvie. Omnicef is used to treat various bacterial infections, including those caused by Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus. The drug is available as a generic medication, as its patent has expired. Key safety considerations include potential allergic reactions and gastrointestinal side effects.
At a glance
| Generic name | CEFDINIR |
|---|---|
| Sponsor | Abbvie |
| Drug class | Cephalosporin Antibacterial [EPC] |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Acute Moraxella catarrhalis bronchitis
- Acute bacterial sinusitis
- Haemophilus Influenzae Bronchitis
- Haemophilus Parainfluenzae Bronchitis
- Haemophilus Parainfluenzae Pneumonia
- Haemophilus influenzae pneumonia
- Infection due to Staphylococcus aureus
- Infective otitis media
- Moraxella Catarrhalis Pneumonia
- Pneumonia due to Streptococcus
- Streptococcal tonsillitis
- Streptococcus Pneumoniae Bronchitis
- Streptococcus pyogenes infection
Common side effects
- Leukopenia
- Increased AST
- Diarrhea
- Rash
- Vomiting
- Cutaneous moniliasis
- Abdominal pain
- Vaginal moniliasis
- Vaginitis
- Abnormal stools
- Dyspepsia
- Hyperkinesia
Drug interactions
- aluminium chloride
Key clinical trials
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Cefdinir Capsules 300 mg, Fasting (PHASE1)
- Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting (PHASE1)
- Cefdinir for Oral Suspension 250 mg/5mL, Fasting (PHASE1)
- Cefdinir Capsules 300 mg, Non-fasting (PHASE1)
- Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting (PHASE2)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |